Hongliang Li

机构：Jiangnan University, University of Electronic Science and Technology of China, Capital Medical University, Wuhan University, Open Targets, Gannan Medical University, Zhongnan Hospital of Wuhan University, Second Affiliated Hospital of Xi'an Jiaotong University, First Affiliated Hospital of Gannan Medical University, Drug Discovery Laboratory (Norway), Renmin Hospital of Wuhan University, Beijing Shijitan Hospital, L-3 Communications (United States) · ORCID：0000-0002-9821-0297

发表论文 514 篇 · 总被引 31796 次 · h-index 83

代表论文

• Lymphoplasmapheresis for Steroid‐Refractory Neuromyelitis Optica Spectrum Disorder: A Real‐World Multicenter Study in China (2025 · CNS Neuroscience & Therapeutics · 被引 9)
• Discovery of a carboxyl fullerene derivative as a new lipid droplet regulator inhibiting MASLD (2025 · Gut · 被引 8)
• Integrated screening identifies GPR31 as a key driver and druggable target for metabolic dysfunction–associated steatohepatitis (2025 · Journal of Clinical Investigation · 被引 7)
• Icaritin inhibits osteoclast differentiation and reduces bone loss by targeting ESR1 to inhibit miR503/RANK pathway (2025 · Frontiers in Pharmacology · 被引 4)
• Chlorinated Guaiane-Type Sesquiterpene Lactones of Natural Origin (2025 · Journal of Natural Products · 被引 4)
• Global, regional, and national burden of acute hepatitis (1990–2021): a systematic analysis of the global burden of disease in 2021 (2025 · Frontiers in Medicine · 被引 4)